The Thoc1 Ribonucleoprotein as a Novel Biomarker for Prostate Cancer Treatment Assignment
Abstract
Active surveillance (AS) is an option for men with low risk prostate cancer in order to reduce over treatment, but few men choose it because current prognostic indicators are imperfect. The objectives of this research are to test whether pThoc1 can improve the assignment of prostate cancer patients to therapy. We have made significant progress on the goals articulated in the Statement of Work. IRB/HRPO approval has been obtained for construction and use of new TMAs (PI Mohler and Goodrich). The TMAs from PCaP have been obtained (PI Mohler and Goodrich). Pathology analysis of 1146 patient specimens is complete and construction of TMAs is complete (PI Mohler). Optimization of TMA staining is complete and staining of all TMAs initiated, with staining of some TMAs complete (PI Goodrich). IRB/HRPO approval for active surveillance specimens has been obtained (PI Mohler, Goodrich). Enrollment of prostate cancer patients on active surveillance is ongoing (PI Mohler). Developing ELISA assays for measuring pThoc1 and pThoc1 autoantibodies is complete (PI Goodrich). IRB/HRPO approval for serum samples has been obtained (PI Mohler, Goodrich). Analysis of serum samples from human prostate cancer patients has been initiated (PI Goodrich). Year 3 of the grant will finish data acquisition and data analysis. Over treatment complicates the clinical management of prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2016
- Accession Number
- AD1033412
Entities
People
- David W Goodrich